Core Points - Stryker will report its financial results for the second quarter of fiscal year 2025 on July 31, 2025 [1] - A press release with summary financial information will be available at approximately 4:05 p.m. ET on the same day [1] - The company will host a webcast at 4:30 p.m. ET to discuss the second quarter results, with an archive available two hours after the live call [2] Company Overview - Stryker is a global leader in medical technologies, focusing on improving healthcare through innovative products and services in MedSurg, Neurotechnology, and Orthopaedics [3] - The company impacts over 150 million patients annually through its offerings [3]

Core Insights - Stryker (SYK) has received FDA clearance for its InCompass Total Ankle System, which enhances its Foot & Ankle portfolio and targets end-stage ankle arthritis [1][4][7] - The InCompass system is designed to improve surgical efficiency and implant alignment, addressing significant mobility issues for patients with ankle arthritis [2][8][9] Company Developments - The InCompass Total Ankle System integrates features from Stryker's existing Inbone and Infinity platforms, developed from extensive clinical data [8][9] - Stryker's Foot & Ankle segment generated $2.4 billion in sales during Q1 2025, accounting for approximately 41% of the company's total revenues of $5.9 billion [10] Market Position and Performance - Following the FDA clearance, Stryker's stock has shown a year-to-date increase of 9.3%, outperforming the industry growth of 6.7% and the S&P 500's gain of 4.4% [3] - The InCompass system is expected to strengthen Stryker's position in the growing foot and ankle reconstruction market, driven by rising cases of ankle arthritis [4][12] Financial Metrics - Stryker currently has a market capitalization of $150.47 billion and an earnings yield of 3.4%, significantly higher than the industry's 0.04% [5] - The company reported an earnings surprise of 4.03% in the last quarter [5] Product Features and Innovations - The InCompass system emphasizes adaptability and efficiency, incorporating advanced technologies for better long-term fixation and streamlined surgical workflows [8][9] - The system is built on Stryker's SOMA platform and utilizes imaging from the Prophecy Surgical Planning System to enhance surgical precision [9] Growth Strategy - Stryker's Foot & Ankle portfolio is a key growth driver within its Orthopaedics segment, focusing on innovation and data-driven design to meet the rising demand for minimally invasive solutions [10][12] - The company aims to capture greater market share and enhance procedure volumes in ambulatory surgical centers [4]

Core Viewpoint - Smith+Nephew has announced a strategic partnership with Standard Health to develop the first Orthopaedic Ambulatory Surgery Centre in the UK, aimed at improving access to advanced joint repair and replacement technologies for both NHS and private patients [1][2]. Group 1: Partnership Details - The new centre will be located in Poole, Dorset, and is expected to open in 2025, serving thousands of patients annually, primarily through NHS referrals [3][4]. - Standard Health will manage the site development and operation, while Smith+Nephew will provide its innovative medical technologies [2][10]. - Standard Health plans to expand by opening an additional 10 sites in the UK over the next three years, totaling 20 by 2030 [2]. Group 2: Operational Model and Benefits - The centre will adopt the Ambulatory Surgery Center (ASC) model from the US, which has proven benefits such as greater procedural efficiency, a 92% patient satisfaction rate, and a 40% reduction in costs for outpatient joint replacements compared to hospital-based surgeries [3][6]. - The UK currently has over 850,000 individuals waiting for orthopaedic surgery, highlighting the need for independent providers to meet this demand [3]. Group 3: Strategic Goals - The partnership aims to redefine the UK independent care provider model for orthopaedics, ensuring a standard quality of care and long-term sustainability for NHS commissioners [4]. - The collaboration is positioned to address the significant waiting times for procedures in the UK, leveraging Smith+Nephew's expertise in ASCs to enhance patient outcomes [4][10].

Core Insights - Stryker reported revenue of $5.87 billion for the quarter ended March 2025, reflecting an 11.9% increase year-over-year and surpassing the Zacks Consensus Estimate of $5.7 billion by 2.88% [1] - The company's EPS for the quarter was $2.84, up from $2.50 in the same quarter last year, exceeding the consensus estimate of $2.73 by 4.03% [1] Financial Performance - Net sales in the United States reached $4.44 billion, exceeding the average analyst estimate of $4.25 billion, representing a year-over-year increase of 13.4% [4] - International net sales totaled $1.43 billion, slightly below the average estimate of $1.44 billion, with a year-over-year growth of 7.3% [4] - Orthopaedics net sales amounted to $2.36 billion, surpassing the average estimate of $2.31 billion, marking a 5% increase year-over-year [4] Segment Performance - MedSurg and Neurotechnology sales were reported at $3.51 billion, exceeding the average estimate of $3.41 billion, with a significant year-over-year increase of 17.1% [4] - Orthopaedics- Trauma and Extremities sales reached $945 million, above the average estimate of $902.89 million, reflecting a 13.9% year-over-year increase [4] - Orthopaedics- Spinal Implants sales were $166 million, falling short of the average estimate of $172.83 million, showing a substantial year-over-year decline of 44.7% [4] Stock Performance - Stryker's shares have returned +1.6% over the past month, contrasting with a -0.5% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the broader market in the near term [3]

Portage, Michigan, May 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the first quarter of 2025: First Quarter Results Reported net sales increased 11.9% to $5.9 billionOrganic net sales increased 10.1%Reported operating income margin of 14.3%Adjusted operating income margin(1) increased 100 bps to 22.9%Reported EPS decreased 17.6% to $1.69Adjusted EPS(1) increased 13.6% to $2.84 First Quarter Net Sales Growth Overview Reported Foreign Currency Exchange Constant Currency Acq ...

Contacts For investor inquiries: Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or jason.beach@stryker.com Portage, Michigan, April 29, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in the Bank of America Securities 2025 Global Healthcare Conference on Tuesday, May 13, 2025, at the Encore at Wynn Hotel in Las Vegas, Nevada. Representing the company will be Preston Wells, Vice President and Chief Financial Officer, and Jason Beach, Vice President, Finance and Inves ...

The current level reflects a downward revision of 0.3% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. In its upcoming report, Stryker (SYK) is predicted by Wall Street analysts to post quarterly earnings of $2.73 per share, reflecting an increase of 9.2% compared to the same period last year. Revenues are forecasted to be $5.7 billion, representing a year-over ...